ribosomal protein L17 pseudogene 50Genealiases: []
Q-omics provides the consensus-scored RPL17P50 profile across patient tissues and cancer cell-line models. RPL17P50 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPL17P50 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPL17P50 RNA expression shows 18,613 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where RPL17P50 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL17P50 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL17P50 survival associations across molecular data types. RPL17P50 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL17P50 RNA expression–survival associations across cancer types. High RPL17P50 expression shows unfavorable associations in UVM, KIRC, ACC, COAD, KIRP and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RPL17P50 RNA expression.
This table summarizes RPL17P50 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL17P50. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL17P50 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, COAD, THCA and BRCA. The KIRC box plot shows higher RPL17P50 RNA expression in tumor versus normal tissue (log2 FC = +1.738, t-test p < 0.001).
This table shows molecular features associated with RPL17P50 in patient tissues and cancer cell lines. In patient samples, RPL17P50 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
